In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Progression of coronary atherosclerosis: importance of adequate lipid control in diabetic patients

Session Poster session 3

Speaker Lorenzo Hernando Marrupe

Congress : ESC Congress 2014

  • Topic : preventive cardiology
  • Sub-topic : Metabolic Syndrome, Insulin, Insulin Resistance
  • Session type : Poster Session
  • FP Number : P2281

Authors : L Hernando Marrupe (Madrid,ES), A Suarez Cuervo (Madrid,ES), R Hernandez Antolin (Madrid,ES), N Gonzalo (Madrid,ES), P Jimenez Quevedo (Madrid,ES), MJ Perez Vizcayno (Madrid,ES), C Macaya (Madrid,ES), J Botas (Madrid,ES), F Alfonso Manterola (Madrid,ES)

Authors:
L. Hernando Marrupe1 , A. Suarez Cuervo2 , R. Hernandez Antolin2 , N. Gonzalo2 , P. Jimenez Quevedo2 , M.J. Perez Vizcayno2 , C. Macaya2 , J. Botas1 , F. Alfonso Manterola3 , 1Alcorcon Hospital Foundation, Department of Cardiology - Madrid - Spain , 2Hospital Clinic San Carlos, Department of Cardiology - Madrid - Spain , 3University Hospital De La Princesa, Department of Cardiology - Madrid - Spain ,

Citation:
European Heart Journal ( 2014 ) 35 ( Abstract Supplement ), 393-394

Background: Intravascular ultrasound (IVUS) imaging represents the predominant approach for evaluating progression of coronary atherosclerosis (CA). IVUS provides a precise and reproducible method for determining changes in coronary atheroma burden. Previous studies have confirmed that low levels of LDL-cholesterol (LDL) are associated with a slower CA progression. However, the potential relationship between adequate control of HDL-cholesterol (HDL) and triglycerides (TG) and CA progression remains unknown.

Objective: We sought to investigate CA progression in relation to the extent of lipid control (LDL, HDL and TG) in diabetic patients.

Methods: One hundred nine diabetic patients (mean age 68±9 years, 34 [31%] female) undergoing serial IVUS studies were analyzed (media time interval 474 days). A validated system for volumetric IVUS analysis (EchoScan, TOMTEC) was used for off-line, three-dimensional reconstruction and volumetric analysis. Target lipid levels were those of current guidelines. Levels of LDL, HDL and TG were carefully monitored. Lumen and external elastic membrane volumes, normalized total atheroma volume (TAV) and percent atheroma volume (PAV) were calculated in the target segment in each patient, at baseline and at follow-up. CA progression was measured and defined as the change of TAV and PAV (ΔTAV and ΔPAV). The primary objective was to determine whether inadequate lipid control in diabetic patients is associated with increased CA progression.

Results: In our population of diabetic patients with a high prevalence of statin therapy (89%), inadequate control of the levels of LDL (LDL >70 mg/dl) was not associated with a greater CA progression. However, diabetic patients with inadequate control of both HDL and TG (HDL <40 mg/dl and TG >150 mg/dl) showed significantly most CA progression as measured by the ΔTAV (7,7±21,9 mm3 vs -3,8±19,3 mm3, p=0,006) and by the ΔPAV (1,2±4,9% vs -0,5±3,4%, p=0,034).

Conclusions: Diabetic dyslipidemia (low HDL and high triglycerides levels) is associated with increased CA progression. These findings suggest the need for intensive lipid control in diabetic patients with coronary artery disease, with especial emphasis to obtain adequate control of HDL and TG levels.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are